Japanese Tobacco Stock News

TSE:5388
TSE:5388Basic Materials

Kunimine Industries Q3 EPS Rebound Challenges Long Term Earnings Decline Narrative

Kunimine Industries (TSE:5388) has put up a solid set of Q3 2026 numbers, with revenue of ¥4.7b and basic EPS of ¥35.47. The latest results come against a backdrop of a 15.7% EPS rebound over the past year and net margin at 7.1%. The company has seen quarterly revenue move from ¥4.1b in Q3 2025 to ¥4.7b in Q3 2026, while basic EPS has shifted from ¥31.09 to ¥35.47 over the same period as trailing twelve month EPS reached ¥96.64 on revenue of ¥16.6b. For investors, the key story in this...
TSE:1939
TSE:1939Construction

Yondenko (TSE:1939) Q3 EPS Strength Challenges Cautious Valuation Narratives

Yondenko (TSE:1939) has put Q3 2026 numbers on the table, with revenue of ¥24.5 billion and basic EPS of ¥29.07, giving investors a fresh read on how the year is shaping up. The company has seen quarterly revenue move from ¥26.3 billion in Q2 2025 to ¥25.5 billion in Q3 2025, then to ¥24.5 billion in Q3 2026. Basic EPS has ranged from ¥32.37 in Q2 2025 to ¥24.85 in Q3 2025 and ¥29.07 in Q3 2026, setting a clear track of how the top and bottom lines have been pacing. With a trailing 12 month...
TSE:3946
TSE:3946Packaging

Tomoku (TSE:3946) Q3 Earnings Jump As Margin Improvement Challenges Bearish Narratives

Tomoku (TSE:3946) has just posted its Q3 2026 numbers, reporting revenue of about ¥57.8b and basic EPS of ¥158.46. This is set against a 28.7% earnings growth rate over the past year and a trailing 12 month EPS of ¥461.29. The company has seen quarterly revenue move between roughly ¥55.0b and ¥59.1b since Q2 2025. Over the same period, basic EPS has ranged from ¥46.09 in Q1 2026 to ¥158.46 this quarter, giving investors a clear line of sight on both top line scale and earnings power. With net...
TSE:8157
TSE:8157Electronic

Tsuzuki Denki (TSE:8157) Margin Improvement To 5.6% Reinforces Bullish Earnings Narratives

Tsuzuki Denki (TSE:8157) has put out its Q3 2026 scorecard, with quarterly revenue of ¥23,889 million and basic EPS of ¥82.93, against trailing twelve month revenue of ¥100.3 billion and EPS of ¥349.91 that reflect the broader earnings growth story over the past year. The company has seen revenue shift from ¥23,456 million in Q3 2025 to ¥23,889 million in Q3 2026, while quarterly EPS moved from ¥38.64 to ¥82.93, presenting a picture of expanding profitability that feeds into the latest net...
TSE:6455
TSE:6455Machinery

Morita Holdings (TSE:6455) Margin Strength In Q3 2026 Supports Bullish Efficiency Narrative

Morita Holdings (TSE:6455) has released its Q3 2026 numbers with revenue of ¥24,474 million and basic EPS of ¥49.56, set against trailing 12 month revenue of ¥117,909 million and EPS of ¥245.92. These figures frame the latest quarter within a broader earnings run rate. The company’s quarterly revenue moved from ¥22,862 million in Q3 2025 to ¥24,474 million in Q3 2026, while basic EPS over the same quarters shifted from ¥40.46 to ¥49.56. The update keeps the focus on how margins and profit...
TSE:7475
TSE:7475Consumer Retailing

Albis Ltd Q3 2026 Thin 1.3% Net Margin Reinforces Profitability Concerns

ALBISLtd (TSE:7475) has put up another quarter of steady numbers, with Q3 2026 revenue at ¥26,315 million and basic EPS of ¥56.12, while trailing twelve month revenue sits at ¥101.4 billion and EPS at ¥159.91. Over recent quarters the company has seen revenue move from ¥24,296 million in Q2 2025 to ¥26,315 million in Q3 2026, with quarterly EPS shifting from ¥31.56 to ¥56.12 as trailing twelve month EPS moved from ¥152.81 to ¥159.91, outlining a story that is as much about the shape of...
TSE:4462
TSE:4462Chemicals

Ishihara Chemical (TSE:4462) Q3 Earnings Show 10.9% Margin Testing Growth Narratives

Fresh off its Q3 2026 report, Ishihara Chemical (TSE:4462) posted revenue of ¥5.9 billion and basic EPS of ¥58.17, with quarterly net income of ¥795 million setting the tone for this update. The company has seen quarterly revenue move from ¥5.6 billion in Q1 2026 to ¥6.0 billion in Q2 2026 and ¥5.9 billion in Q3 2026. Basic EPS ranged from ¥33.56 in Q1 2026 to ¥59.33 in Q2 2026 and ¥58.17 in Q3 2026. Together, these figures point to a set of results where margins and earnings quality are...
TSE:1959
TSE:1959Construction

Kraftia (TSE:1959) Q3 EPS Jump Tests Premium P/E And Growth Narratives

Kraftia (TSE:1959) Q3 2026 earnings snapshot Kraftia (TSE:1959) has just posted its Q3 2026 numbers, with revenue of ¥111.5 billion and basic EPS of ¥148.82, supported by net income excluding extra items of ¥10,527 million. The company has reported quarterly revenue of ¥112.1 billion in Q2 2025, ¥109.8 billion in Q3 2025, ¥144.9 billion in Q4 2025, and ¥100.6 billion, ¥107.2 billion and now ¥111.5 billion in the first three quarters of 2026, while basic EPS has ranged from ¥76.49 to ¥148.82...
TSE:4519
TSE:4519Pharmaceuticals

Chugai Pharmaceutical (TSE:4519) Earnings Growth And 34.5% Margin Test Premium Valuation Narrative

Chugai Pharmaceutical (TSE:4519) has wrapped up FY 2025 with fourth quarter revenue of ¥346.3 billion and basic EPS of ¥78.03, rounding out a year in which trailing twelve month revenue came in at ¥1.26 trillion and EPS reached ¥263.73. Over the past few quarters, the company has seen revenue move from ¥288.5 billion and EPS of ¥59.09 in Q1 2025 to ¥346.3 billion and EPS of ¥78.03 in Q4, while trailing twelve month revenue and EPS have shifted from ¥1.17 trillion and ¥235.39 a year earlier to...
TSE:6366
TSE:6366Construction

Is It Too Late To Consider Chiyoda (TSE:6366) After A 323% One Year Surge?

If you are wondering whether Chiyoda shares still offer value after a strong run, this article walks through what the current price might be implying about the business. Chiyoda's share price, which last closed at ¥1,282, comes with sizeable reported returns of 43.4% over 7 days, 74.4% over 30 days, 53.7% year to date and 323.1% over 1 year. These moves sit alongside ongoing investor interest in the capital goods space and renewed attention on companies listed on the Tokyo Stock Exchange...
TSE:6501
TSE:6501Industrials

Hitachi (TSE:6501) Margin Improvement Reinforces Bullish Earnings Narrative Despite Premium P/E

Hitachi Q3 2026 earnings snapshot Hitachi (TSE:6501) has reported new figures for Q3 2026, posting revenue of ¥2,714.4b and basic EPS of ¥36.64, with trailing twelve month EPS at ¥180.73. The company’s revenue increased from ¥2,465.2b in Q3 2025 to ¥2,714.4b in Q3 2026. Over the same period, basic EPS rose from ¥30.20 to ¥36.64, alongside trailing twelve month net income of ¥823.50b. With a trailing net margin of 8%, the latest figures give investors a clearer view of current...
TSE:7182
TSE:7182Banks

Is JAPAN POST BANK (TSE:7182) Recasting Its Fee Model With a Unified Asset Management Platform?

Japan Post Bank Co., Ltd. recently held a board meeting to consider creating Japan Post Bank Asset Management Co., Ltd. via an absorption-type merger with Japan Post Co., Ltd., integrating JP Asset Management and Japan Post Investment into a single platform. This planned integration of retail investment trusts and private equity reflects Japan Post Bank’s effort to deepen client relationships and enhance fee-based income within Japan’s push to build a stronger asset management hub. We’ll now...
TSE:7267
TSE:7267Auto

Assessing Honda Motor (TSE:7267) Valuation After Prelude Relaunch And New Materials Research Investments

The return of the 2026 Honda Prelude and Honda Motor (TSE:7267) R&D's use of Matlantis CSP put product relaunch and materials research in focus, giving investors fresh context for assessing the stock. See our latest analysis for Honda Motor. Against this backdrop, Honda Motor's share price at ¥1,555 sits after a mixed few months, with a 1-day share price return of 1.47% contrasting with a softer 7-day move and a 10.02% 1-year total shareholder return that points to momentum built over a...
TSE:8308
TSE:8308Banks

Resona Holdings (TSE:8308) Valuation After Strong Nine Month Earnings And Higher EPS

Resona Holdings earnings trigger fresh look at the stock Resona Holdings (TSE:8308) has just reported nine month results to December 31, 2025, with higher net interest income, net income and earnings per share, giving investors fresh information to reassess the bank’s shares. See our latest analysis for Resona Holdings. The latest earnings update comes after a strong run in the shares, with a 30 day share price return of 19.86% and a 1 year total shareholder return of 57.37%. Multi year total...
TSE:6988
TSE:6988Chemicals

Assessing Nitto Denko (TSE:6988) Valuation After Revised Guidance And Nine Month Results

Why Nitto Denko (TSE:6988) Is Back on Investors’ Radar Nitto Denko (TSE:6988) is drawing fresh attention after revising full year guidance to revenue of ¥1,027,000m and net profit of ¥136,000m, alongside nine month results showing sales of ¥786,195m and slightly lower net income year on year. See our latest analysis for Nitto Denko. The updated guidance and nine month sales figure seem to have landed in a market that has recently turned cautious, with a 30 day share price return of 7.78% and...
TSE:8593
TSE:8593Diversified Financial

Mitsubishi HC Capital (TSE:8593) Valuation Check After Space BD Alliance And Space Finance Expansion

Mitsubishi HC Capital (TSE:8593) has taken a fresh step into the space sector by leading Space BD’s Series C funding round, forming a capital and business alliance focused on new service models and financing solutions. See our latest analysis for Mitsubishi HC Capital. The Space BD alliance comes as Mitsubishi HC Capital’s share price has recorded an 11.86% 90 day share price return and a 35.30% 1 year total shareholder return, pointing to momentum that has built steadily rather than in a...
TSE:3923
TSE:3923Software

Assessing Rakus (TSE:3923) Valuation After Strong December 2025 Sales Update

December sales update and why it matters for Rakus shareholders Rakus (TSE:3923) reported preliminary unaudited consolidated sales of ¥5,239 million for December 2025, equal to 124.2% year on year, a data point that naturally puts recent share price moves in context for investors. See our latest analysis for Rakus. The December sales update arrives after a weak stretch for the share price, with a 30 day share price return of 15.33% decline and a 1 year total shareholder return of 9.25%...
TSE:9962
TSE:9962Machinery

Will MISUMI’s AI Manufacturing Push and Fictiv Integration Shift MISUMI Group's (TSE:9962) Narrative

MISUMI Group Inc. recently held a board meeting on January 30, 2026 to review its consolidated business and dividend forecasts, and earlier in the month appointed Fictiv co-founder Dave Evans as President of MISUMI Americas to lead integration efforts. This leadership change and planned unification of MISUMI and Fictiv into an AI-powered manufacturing platform mark a meaningful shift in how the company aims to deliver both standard and custom solutions across the Americas. Next, we will...
TSE:9434
TSE:9434Wireless Telecom

SoftBank (TSE:9434) Valuation Check After Infrinia AI Cloud OS And V2X Expansion News

SoftBank (TSE:9434) is drawing fresh attention after its Infrinia team introduced Infrinia AI Cloud OS for GPU based AI data centers, alongside a deeper collaboration with Eye Net Mobile on V2X safety solutions in Japan. See our latest analysis for SoftBank. These AI and V2X announcements arrive after a mixed period for the stock. The 1 year total shareholder return of 8.54% contrasts with softer year to date and 90 day share price returns, which suggests momentum has cooled recently despite...
TSE:8609
TSE:8609Capital Markets

Okasan Securities Group (TSE:8609) Margin Improvement Challenges Bearish Earnings Narratives

Okasan Securities Group (TSE:8609) has posted Q3 2026 revenue of ¥25,351 million and basic EPS of ¥27.88, with trailing 12 month EPS at ¥69.41 and net income of ¥13,920 million reflecting its recent earnings run rate. The company has seen revenue move from ¥19,971 million and EPS of ¥16.64 in Q2 2025 to ¥25,351 million and EPS of ¥27.88 in Q3 2026, while trailing 12 month revenue sits at ¥85,667 million. With net profit margin on the trailing numbers at 16.2%, the latest quarter keeps the...
TSE:6645
TSE:6645Electronic

Assessing OMRON (TSE:6645) Valuation After Weak 1 Year Returns And A Higher P/E Multiple

Event context and recent share performance OMRON (TSE:6645) has recently drawn investor attention after a period of weaker share performance, with the stock showing a 1.1% gain over the past day but declines over the past week, month, and past 3 months. That mixed picture, combined with the current share price of ¥3,917 and recent annual revenue and net income figures, is prompting some investors to reassess how the market is currently valuing OMRON’s broad automation and healthcare...
TSE:9107
TSE:9107Shipping

Did Northern Lights CO2 Carrier Charter Just Shift Kawasaki Kisen Kaisha's (TSE:9107) Investment Narrative?

On 29 January 2026, MISC Berhad announced that Kawasaki Kisen Kaisha, in a 50:50 joint venture with MISC, had signed a ten-year time charter for a new 12,000-cubic-metre liquefied carbon dioxide carrier with Norway’s Northern Lights JV, with a second similar charter expected in April 2026. This agreement anchors Kawasaki Kisen Kaisha in the emerging carbon capture and storage shipping value chain, connecting European CO2 emitters with permanent offshore storage in Norway. We’ll now examine...
TSE:6305
TSE:6305Machinery

Hitachi Construction Machinery (TSE:6305) Margin Compression Challenges Bullish Earnings Growth Narratives

Hitachi Construction Machinery (TSE:6305) has put fresh numbers on the table for Q3 2026, reporting revenue of ¥325.3 billion and basic EPS of ¥86.76, with net income excluding extraordinary items at ¥18,456 million. The company has seen quarterly revenue move between ¥325.3 billion and ¥380.0 billion over the last six reported periods, while basic EPS has ranged from ¥31.96 to ¥140.12. This gives investors a broad view of how earnings power tracks against a relatively steady top line and...
TSE:4523
TSE:4523Pharmaceuticals

Eisai (TSE:4523) Is Down 5.9% After Leqembi Subcutaneous Priority Review News - Has The Bull Case Changed?

In late January 2026, BioArctic’s partner Eisai reported regulatory progress for Leqembi (lecanemab), including an EMA filing for less frequent IV maintenance dosing and a US FDA Priority Review for a weekly subcutaneous autoinjector starting regimen in early Alzheimer’s disease. This shift toward at-home, less resource-intensive administration could materially influence how Leqembi is used across the treatment journey, potentially reshaping Eisai’s Alzheimer’s franchise profile. We will now...